This study assessed a handheld optical device using autofluorescence imaging (excitation 405 ± 20 nm) as a noninvasive adjunct to identify early or subclinical actinic cheilitis (AC). The approach aimed to detect areas of altered lip mucosa that might represent potentially malignant change and to select sites for biopsy confirmation.
Twenty-five individuals were screened with the autofluorescence device. Areas demonstrating altered fluorescence were biopsied for histologic confirmation of AC. Of the 25 screened subjects, 19 had confirmed actinic cheilitis, and 17 completed the posttreatment follow-up reported in the abstract. The source does not provide detailed demographic breakdowns beyond the counts, nor does it report inclusion/exclusion criteria in the abstract.
Lip autofluorescence was recorded with a handheld device operating at an excitation band centered on 405 nm with ±20 nm bandwidth. The device produced grayscale intensity images that were quantified to compare lesional and healthy tissue. Areas of altered fluorescence were targeted for biopsy to establish diagnostic confirmation.
Patients with biopsy-confirmed AC were treated with topical 1% methylene blue (MB) followed by photodynamic illumination. Each participant received five MB-PDT sessions. Illumination used a 660 nm red laser at 100 mW, delivering 120 seconds per point. The abstract does not specify the interval between sessions, total treatment field dimensions, or anesthetic/analgesic measures.
Grayscale fluorescence intensity was quantified before the MB-PDT course and measured again at 30 days after treatment completion. The analysis compared mean intensity values and variability measures to assess tissue response to therapy.
Autofluorescence imaging identified areas that, on biopsy, proved to be actinic cheilitis in 19 of 25 screened individuals. At baseline, lesional tissue displayed higher autofluorescence intensity than adjacent healthy lip mucosa, supporting the method’s utility in lesion detection.
Following the five-session MB-PDT regimen, the mean grayscale intensity and the variability of intensity among sampled areas significantly decreased, which the authors interpret as an objective sign of tissue response to photodynamic therapy. The abstract does not report numerical values for pre- and posttreatment intensities, effect sizes, or p-values.
The authors note that smokers exhibited a smaller reduction in fluorescence intensity after MB-PDT compared with non-smokers. The abstract does not provide counts of smokers versus non-smokers, statistical comparisons, or potential mechanistic explanations within the reported text.
The findings support the combined use of autofluorescence imaging and methylene blue–mediated photodynamic therapy (MB-PDT) as a practical approach for early detection and noninvasive monitoring of AC in high-risk patients. Autofluorescence imaging may help detect subclinical changes and guide targeted biopsy, while MB-PDT appears to produce measurable reductions in autofluorescence intensity consistent with tissue response.
The abstract lacks several details that would be important for clinical interpretation and implementation: it does not report numerical pre/post intensity values, statistical test results, confidence intervals, or adverse event and safety data. Treatment session intervals, precise lesion sizes or locations, long-term outcomes, and histologic grading after therapy are not provided in the abstract. Where such details are absent in the source, they are not inferred here.
According to the authors, handheld autofluorescence imaging enables early detection of actinic cheilitis and can be used to noninvasively monitor response after 1% methylene blue–mediated PDT. The combined strategy may facilitate early intervention in patients at high risk for lip epithelial malignancy. Clinicians considering adoption should review the full manuscript for complete methodology, safety data, quantitative outcomes, and any procedural specifics not reported in the abstract.